Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |
---|---|
First Received Date † | June 4, 2008 |
Last Updated Date | October 17, 2008 |
Start Date † | |
Current Primary Outcome Measures † |
Comparative changes before and after treatments in each group for Asthma Control Questionnaire (ACQ) |
Original Primary Outcome Measures † | Same as current |
Change History | Complete list of historical versions of study NCT00691951 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures † |
|
Original Secondary Outcome Measures † | Same as current |
Descriptive Information | |
Brief Title † | Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects |
Official Title † | Comparative Effects of Budesonide and Budesonide/Formoterol (Symbicort) on Asthma Control in Smoking Asthmatic Subjects: A Pilot Study |
Brief Summary | A reduced response to inhaled corticosteroids (ICS) has been reported in smoking compared to non-smoking asthmatic patients. However, the comparative response to other currently prescribed medications such as combination therapy of long-acting beta agonists and ICS remain to be further evaluated. No significant differences were found between our group of subjects in regard to changes in asthma control pulmonary function and airway inflammation following budesonide or the association of budesonide with formoterol for a period of 2 months. This should be further explored in larger groups of subjects. |
Detailed Description | |
Study Phase | Phase III |
Study Type † | Interventional |
Study Design † | |
Condition † | Asthma |
Intervention † | Drug: budesonide and budesonide/formoterol |
Study Arms / Comparison Groups | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|
Recruitment Information | |
Recruitment Status † | Completed |
Enrollment † | |
Completion Date | |
Primary Completion Date | |
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
Gender | Both |
Ages | 18 Years to 45 Years |
Accepts Healthy Volunteers | No |
Contacts †† | |
Location Countries † | Canada |
Expanded Access Status | |
Administrative Information | |
NCT ID † | NCT00691951 |
Responsible Party | Louis-Philippe Boulet, Laval University |
Secondary IDs †† | |
Study Sponsor † | Laval University |
Collaborators †† | AstraZeneca |
Investigators † | |
Information Provided By | Laval University |
Verification Date | June 2008 |
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |